Russia approves Onglyza for type 2 diabetes
This article was originally published in Scrip
Executive Summary
Russia's ministry of healthcare and social development has approved Bristol-Myers Squibb/AstraZeneca's Onglyza (saxagliptin) to treat type 2 diabetes. The product is expected to enter the market next month.